Ad
related to: lupus with immunosuppressive medication icd 10 plaquenil- HCPs: Official Resources
Tools for you and your practice
to help you prescribe LUPKYNIS®.
- Starting LUPKYNIS®
Get info and resources to help
start your patient on LUPKYNIS®.
- Important Safety Info
Visit Official HCP Website
for full product information.
- Safety & Efficacy Profile
View LUPKYNIS® results in clinical
trials. Adverse reaction info.
- HCPs: Official Resources
Search results
Results from the WOW.Com Content Network
Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth, often in the form of hydroxychloroquine sulfate. [3]
Furthermore, anti-histone antibodies can also be positive in drug-induced lupus. [citation needed] Anti-Histone antibodies are positive in up to 95% of patients with drug induced lupus. The most common medications associated with drug induced lupus are hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. [9]
Treatment consists primarily of immunosuppressive drugs (e.g., hydroxychloroquine and corticosteroids). A second-line drug is methotrexate in its low-dose schedule. [18] [19] In 2011, the U.S. Food and Drug Administration (FDA) approved the first new drug for lupus in more than 50 years to be used in the US, belimumab. [20]
Hydroxychloroquine was approved by the FDA for lupus in 1955. [120] Some drugs approved for other diseases are used for SLE 'off-label'. In November 2010, an FDA advisory panel recommended approving belimumab (Benlysta) as a treatment for the pain and flare-ups common in lupus. The drug was approved by the FDA in March 2011. [121] [122]
Undifferentiated connective tissue disease (UCTD) (also known as latent lupus or incomplete lupus [1]) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease .
The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., [3] [4] and the term was introduced by Leroy [5] in 1980.
Subacute cutaneous lupus erythematosus (SCLE ) is a clinically distinct subset of cases of lupus erythematosus that is most often present in white women aged 15 to 40, consisting of skin lesions that are scaly and evolve as poly-cyclic annular lesions or plaques similar to those of plaque psoriasis.
Mycophenolic acid is an immunosuppressant medication used to prevent rejection following organ transplantation and to treat autoimmune conditions such as Crohn's disease and lupus. [12] [13] Specifically it is used following kidney, heart, and liver transplantation. [13] It can be given by mouth or by injection into a vein. [13]
Ad
related to: lupus with immunosuppressive medication icd 10 plaquenil